Join us for the inaugural RMIP Research Spotlight featuring Dr. Tim Kamp from the University of Wisconsin.
Wednesday, December 4th 3:00-3:30 PM ET Register here
The adult human heart following a large myocardial infarction is unable to regenerate heart muscle and instead forms scar with the risk of progressive heart failure. Large animal studies have shown that intramyocardial injection of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) following a myocardial infarction result in cell grafts but also ventricular arrhythmias. In this research spotlight, results will be presented from a preclinical study to evaluate the biomanufacturing, safety, and efficacy of intramyocardial injection of committed cardiac progenitor cells derived from iPSCs, combined with cardiac fibroblast-derived extracellular matrix to enhance cell retention that suggests a promising new avenue for treating heart failure.
Jeran Stratford
Join us for the inaugural RMIP Research Spotlight featuring Dr. Tim Kamp from the University of Wisconsin.
The adult human heart following a large myocardial infarction is unable to regenerate heart muscle and instead forms scar with the risk of progressive heart failure. Large animal studies have shown that intramyocardial injection of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) following a myocardial infarction result in cell grafts but also ventricular arrhythmias. In this research spotlight, results will be presented from a preclinical study to evaluate the biomanufacturing, safety, and efficacy of intramyocardial injection of committed cardiac progenitor cells derived from iPSCs, combined with cardiac fibroblast-derived extracellular matrix to enhance cell retention that suggests a promising new avenue for treating heart failure.